Zobrazeno 1 - 7
of 7
pro vyhledávání: ''
Publikováno v:
JAMA Dermatol
This cohort study evaluates the association of etanercept treatment with outcomes of reactive infectious mucocutaneous eruption in hospitalized children and adolescents.
Publikováno v:
JAMA Dermatol
Importance Childhood-onset lupus erythematosus panniculitis (LEP) is a rare and chronic disfiguring disease. A paucity of literature exists on the clinical manifestations of this disease and how best to treat it. Objectives To describe the clinical f
Autor:
Carrie Diamond, Gabriele Richard, April Zhang, Dawn H. Siegel, Sabine Duchatelet, Anna Yasmine Kirkorian, India Hill, Nikita Lakdawala, Richard L. Tower, Kalyani Marathe, Alain Hovnanian, Flora Watanabe, Yaser Diab
Publikováno v:
JAMA Dermatol
Importance Olmsted syndrome is a rare and disabling genodermatosis for which no successful treatment is currently available. Objective To evaluate the clinical response to the mammalian target of rapamycin (mTOR) inhibitor sirolimus and/or the epider
Publikováno v:
JAMA Dermatology. 154:627
Publikováno v:
JAMA Dermatology. 154:111
Autor:
Ulrich Mrowietz, Zsuzsanna Szalai, Megha M. Tollefson, Irene Lara-Corrales, Inge M G J Bronckers, Ruth Murphy, Sandra Philipp, Wynnis L. Tom, Kelly M. Cordoro, Emmanuel Mahé, Jo Lambert, Eulalia Baselga, Amy S. Paller, Ruth Ann Vleugels, Dennis P. West, Marcia Hogeling, Claus Zachariae, Wietske Kievit, Elaine C. Siegfried, Leah Belazarian, Marieke M B Seyger, Kristen E. Holland, Alex Alexopoulos
Publikováno v:
Jama Dermatology, 153, 11, pp. 1147-1157
Jama Dermatology, 153, 1147-1157
Jama Dermatology, 153, 1147-1157
Importance Use of systemic therapies for moderate to severe psoriasis in children is increasing, but comparative data on their use and toxicities are limited. Objective To assess patterns of use and relative risks of systemic agents for moderate to s
Autor:
Ayumi Nakamura, Mari Tanaka, Ichiro Katayama, Misa Hayashi, Mari Wataya-Kaneda, Shoji Matsumoto, Koji Yamamoto
Publikováno v:
JAMA Dermatology. 153:39
Inhibitors of mammalian target of rapamycin complex 1, such as sirolimus, effectively target skin lesions in tuberous sclerosis complex (TSC). However, systemic treatment causes adverse effects, and topical sirolimus has shown promise in the treatmen